(LEGN) Legend Biotech - Ratings and Ratios

Legend Biotech Corporation (NASDAQ:LEGN) is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative cell therapies, primarily for oncology and other unmet medical needs. The company operates across the United States, China, and Europe, leveraging its expertise in cell therapy manufacturing and clinical development. Its lead product, cilta-cel, is a groundbreaking chimeric antigen receptor (CAR-T) therapy approved by the FDA for the treatment of adults with relapsed or refractory multiple myeloma (MM). This therapy has demonstrated significant clinical efficacy, with a high overall response rate and durable remissions in clinical trials.

Beyond cilta-cel, Legend Biotech has a robust pipeline of autologous CAR-T candidates targeting a wide range of cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, and solid tumors such as gastric, esophageal, pancreatic, colorectal, hepatocellular, small cell lung, and non-small cell lung cancers. The company is also advancing next-generation allogeneic gamma delta CAR-T and CAR-NK cell therapies, which are currently in Phase 1 clinical trials in China. These allogeneic programs aim to address B-cell maturation antigen (BCMA) in multiple myeloma, offering a potential off-the-shelf alternative to autologous therapies.

Legend Biotech has established strategic collaborations to accelerate its growth. It has a partnership with Janssen Biotech, Inc., for the development and commercialization of cilta-cel, and a licensing agreement with Novartis Pharma AG for CAR-T therapies targeting delta-like ligand protein 3. These partnerships underscore the companys commitment to expanding its therapeutic reach and improving patient access to innovative treatments. Founded in 2014 and headquartered in Somerset, New Jersey, Legend Biotech operates as a subsidiary of Genscript Biotech Corporation, with a strong focus on translational research and manufacturing excellence.

Ticker Symbol: LEGN
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Biotechnology

Average Volume 20d: 1,321,135
Last Price: 34.28
SMA 20: 32.83
SMA 50: 35.06
SMA 200: 42.61
ATR: 1.69

Market Cap: 5,876.77M USD
P/E: None
P/E Forward: 1,000.00
P/B: 5.65
P/S: 9.37
RoE: -17.01

3-Month Forecast:
- The stock is likely to consolidate near the SMA 20 and SMA 50 levels, with potential resistance at $35.06 and $32.83 as key support.
- The ATR of 1.69 suggests moderate volatility, with price fluctuations expected to remain within a $3-4 range.
- The gap between the last price ($34.28) and the SMA 200 ($42.61) indicates potential long-term downside risks if the stock fails to breach the SMA 50 level.
- The high P/B ratio of 5.65 reflects investor confidence in the companys growth prospects, despite the lack of profitability (RoE: -17.01%).
- The forward P/E of 1,000.00 suggests high market expectations for future earnings, though this may pose risks if the company fails to meet growth targets.
- The P/S ratio of 9.37 indicates a premium valuation relative to sales, highlighting the markets focus on the companys pipeline potential.